SCHAUMBURG, Ill., Aug 10–(HSMN NewsFeed)–APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ ), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) …
Biopharmaceuticals, Generics, FDA
APP Pharmaceuticals, idarubicin, Idamycin, Pfizer

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “APP Pharmaceuticals Receives Approval for Idarubicin HCI Injection”
Leave a Comment